

2.5 Patient status

As of March 2010, a total of 1,630 breast cancer patients and survivors were followed up for an average period of 2.2 years (range 0.01-16.7 years). Out of 1,630 patients, 35 (2.0%) patients had locoregional recurrences with a mean time to locoregional recurrence of 2.5 years (range: 0.6-8.0 years) and 45 (2.8%) patients had distant recurrence with a mean time to distant recurrence of 3.2 years (range: 0.4-9.6 years) (Table 2.5.1).

Table 2.5.1 Follow-up of 1,630 subjects

	Number (%)
Follow-up period (N=1,630)	
< 1 year	391(24.0%)
1-2 years	628(38.5%)
2-5 years	471(28.9%)
>5 years	140(8.6%)
Mean follow-up period	2.2 ± 2.0years
Median follow-up period	1.2years
Range (years)	0.01-16.7years
Locoregional recurrence	
No. of locoregional recurrence	35(2.0%)
Mean time to locoregional recurrence	2.5years
Median time to locoregional recurrence	1.9years
Distant recurrence	
No. of distant recurrence	45(2.8%)
Mean time to distant recurrence	3.2years
Median time to distant recurrence	2.7years
Mortality	
No. of deaths from breast cancer	5(0.3%)
No. of deaths from unrelated cause	0(0%)

Five patients (0.3%) died from breast cancer during the follow-up period and their mean survival time was 2.7 years from their initial diagnosis (range: 1.6-5.2 years) (Table 2.5.2).

Table 2.5.2 Characteristics of breast cancer-specific deaths

Case	Cancer Stage	Age at diagnosis	Relative survival time (years)	Distant organs involved	Molecular subtype	Outcome event
A	Stage IIIC	35.1	5.2	Liver	ER+PR+HER2-	Cancer-specific death
B	Stage IIIA	40.8	1.6	Bone and liver	Unknown	Cancer-specific death
C	Stage IIA (Tis, N1, M0)	44.9	2.4	Lung	Unknown	Cancer-specific death
D	Unstaged	47.9	2.5	Unknown	ER+PR+HER2-	Cancer-specific death
E	Unstaged	75.1	1.9	Bone and liver	ER+PR+HER2-	Cancer-specific death